br+/nad with tirzepatide Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review BR+ NAD vs. NAD+ Therapy:

Cardiovascular considerations exist for both medications

Eli Lilly published the results of its ATTAIN-1b trial for obesity in September 2025 7 , which compared orforglipron to placebo in more than 3,100 adults without diabetes, with a BMI of 30+ or 27-30 with an obesity-related complication including hypertension, dyslipidaemia, cardiovascular disease or obstructive sleep apnoea and a history of at least one patient-reported unsuccessful dietary effort to lose body weight, who have tried unsuccessfully to lose weight with diet alone

When appropriate, compounded GLP-1 medications may be prescribed through a trusted compounding pharmacy partner

Taking any medicine for things not listed on its label should be done with care

While standard L-carnitine is highly effective at supporting skeletal muscle and cardiovascular tissue, it struggles to penetrate the central nervous system

Digestive issues like nausea, gas, and changes in bowel movements are most common, particularly with berberine-containing products